Persistent STAT5 activation reprograms the epigenetic landscape in CD4 + T cells to drive polyfunctionality and antitumor immunity
- 8 October 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 5 (52)
Abstract
Persistent STAT5 activation endows antitumor CD4 + T cells with desirable functional features that optimize adoptive T cell therapy.Keywords
Funding Information
- American Cancer Society (IRG14-193-01)
- NIH Office of the Director (1R01CA215523)
- NIH Office of the Director (1R03CA212829)
- NIH Office of the Director (1R01CA238514)
- National Institute of Allergy and Infectious Diseases (R37AI34495)
This publication has 92 references indexed in Scilit:
- Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotypeJournal of Experimental Medicine, 2012
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- Differential oestrogen receptor binding is associated with clinical outcome in breast cancerNature, 2012
- Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infectionProceedings of the National Academy of Sciences, 2011
- Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cellsBlood, 2010
- Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safetyLeukemia, 2010
- Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanomaJournal of Experimental Medicine, 2010
- Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hostsJournal of Experimental Medicine, 2010
- Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell ImmunityScience, 2008
- Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1New England Journal of Medicine, 2008